Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6829825 | 0.89 | TDP1 (0.49) | KMT2ATDP1MEN1NPSR1CA12 | |
| SCHEMBL9407115 | 0.83 | TDP1 (0.45) | KMT2ALMNATDP1MEN1NPSR1 | |
| SCHEMBL29449953 | 0.82 | GAA (0.46) | GAAKMT2ALMNAMEN1NPSR1 | |
| SCHEMBL107781 | 0.81 | HPGD (0.48) | GAAKMT2ALMNATDP1MEN1 | |
| SCHEMBL29449956 | 0.80 | GAA (0.45) | GAAKMT2ALMNAMEN1NPSR1 | |
| SCHEMBL2597681 | 0.80 | POLB (0.44) | GAAKMT2ATDP1MEN1NPSR1 | |
| SCHEMBL16868487 | 0.80 | GAA (0.49) | GAAKMT2ALMNAMEN1NPSR1 | |
| SCHEMBL23057071 | 0.79 | TDP1 (0.43) | KMT2ATDP1MEN1NPSR1CA12 | |
| SCHEMBL11140840 | 0.79 | POLB (0.54) | KMT2ATDP1MEN1NPSR1CA12 | |
| SCHEMBL6898817 | 0.79 | TDP1 (0.43) | KMT2ATDP1MEN1NPSR1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326777-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HEPAITECH BEIJING BIOPHARMA TECH CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| EP-4097099-B9 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | Mirati Therapeutics, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2025043191-A1 | PRC2 INHIBITORS FOR USE IN TREATING SICKLE CELL DISEASE | ORIC PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | disclosed |
| CN-1136198-C | Novel benzyl pyrimidines | ��������ҩ�ɷ�����˾ | 2004-01-28 | — | — | CN | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-6353083-B1 | CONJUGATED COPOLYMER COMPRISING UNITS DERIVED FROM 9-SUBSTITUTED FLUORENE MONOMERS AND/OR 9,9-DISUBSTITUTED FLUORENE MONOMERS AND TWO DISTINCT RESIDUAL MONOMERIC UNITS THAT HAVE HOLE TRANSPORTING PROPERTIES | THE DOW CHEMICAL COMPANY | 2002-03-05 | — | — | US | disclosed |
| CN-1337987-A | Fluorene copolymers and devices made therefrom | DOW CHEMICAL CO (US) | 2002-02-27 | — | — | CN | disclosed |
| EP-1155096-A1 | FLUORENE COPOLYMERS AND DEVICES MADE THEREFROM | THE DOW CHEMICAL COMPANY (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000046321-A1 | FLUORENE COPOLYMERS AND DEVICES MADE THEREFROM | THE DOW CHEMICAL COMPANY (US) | 2000-08-10 | — | — | WO | disclosed |
| CN-1166831-A | Novel benzyl pyrimidines | HOFFMANN LA ROCHE (CH) | 1997-12-03 | — | — | CN | disclosed |
| EP-0303186-B1 | Aryl phosphorus derivatives, their preparation and their use | BASF AG (DE) | 1993-11-10 | — | — | EP | disclosed |
| EP-0303186-A2 | Aryl phosphorus derivatives, their preparation and their use | BASF Aktiengesellschaft (DE) | 1989-02-15 | — | — | EP | disclosed |
| US-4069247-A | Preparation of phosphonic and/or phosphinic acids | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | GAA 1076/4885KMT2A 4022/4885LMNA 3168/4885 |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | GAA 3443/4885KMT2A 8/4885LMNA 3643/4885 |
| US-12252493-B2 | Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer | BMI1, EZH2, SUZ12 | GAA 2893/4885KMT2A 47/4885LMNA 3710/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | GAA 3417/4885KMT2A 28/4885LMNA 3805/4885 |
| US-20250326777-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | MRGPRX4, MRGPRX1, MRGPRX2 | GAA 169/4885KMT2A 2511/4885LMNA 1156/4885 |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | BMI1, EZH2, SUZ12 | GAA 2893/4885KMT2A 47/4885LMNA 3710/4885 |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | EZH2, BMI1, EZH1 | GAA 1232/4885KMT2A 10/4885LMNA 3326/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | GAA 2256/4885KMT2A 51/4885LMNA 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.